Eligibility to randomize into the A3 Trial or A45 Trial is based on the screening PET imaging results. 3 key findings →
Design: clinical trial Evidence: moderate
Full summary, score breakdown and related studies → Original source
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Eligibility to randomize into the A3 Trial or A45 Trial is based on the screening PET imaging results. 3 key findings →
Design: clinical trial Evidence: moderate
Full summary, score breakdown and related studies → Original source
Multidomain intervention studies conducted so far appear to have mixed results and substantial variability in target populations, format and intensity of interventions, choice of control conditions, and outcome measures. 2 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
Dementia is a major global health challenge, as its burden on society will increase with population aging. 2 key findings →
Design: cross-sectional Evidence: high
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) remains a widespread cause of dementia globally, and its prevalence is increasing due to the aging population. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
The concept of cognitive reserve (CR) suggests that innate intelligence or aspects of life experience like educational or occupational attainments may supply reserve, in the form of a set of skills or repertoires that allows some people to cope with progressing Alzheimer's disease (AD) pathology better than others. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Purpose of the study There is a global imperative to increase awareness of the emerging evidence on physical activity (PA) among older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is the primary cause of age-related dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Falls remain common in older people, with higher prevalence and morbidity in those who are cognitively impaired. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Physical activity improves overall health and reduces the risk of many negative health outcomes and may be effective in improving cognition, independent functioning, and psychological health in older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cognitive impairment can be influenced by a number of factors. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Physical activity reduces the risk of cognitive impairment, mainly vascular dementia, in older people living independently. 1 key finding →
Participants: 90 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Hearing loss is a modifiable risk factor for dementia in older adults. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Abnormal deposition and intercellular propagation of α-synuclein plays a central role in the pathogenesis of disorders such as Parkinson's Disease (PD) and dementia with Lewy bodies (DLB). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There were observable geographic variations in education (range 13.4-16.2 years, Figure 1), age (range 66.7-72.4 years) and severable modifiable risk factors for dementia across Tasmania, Australia. 5 key findings →
Design: longitudinal study Participants: 8,891 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The findings from the AHEAD Study screening process and longitudinal data from the LEARN Study are providing critical data to guide future prevention trial design. 5 key findings →
Design: longitudinal study Participants: 1,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Enhancing CRC screening, early detection, and public health interventions can significantly reduce CRC-related mortality. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Preventing dementia and Alzheimer's disease (AD) is a global priority. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The 2024 Lancet Commission Report on dementia prevention has identified 14 modifiable risk factors that account for approximately 45% of global dementia cases. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
What we eat is a cornerstone of cardiovascular disease (CVD) prevention, but health professionals may not have a clear understanding of the current evidence-based research to underpin eating habits and recommendations. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A European Task Force has recently developed and published the concept and protocols for the setup of the innovative health offer of Brain Health Services for the secondary prevention of dementia and cognitive impairment (dBHS). dBHS are outpatient health care facilities where adult persons can find an assessment of their risk of developing cognitive impairment and dementia, have their risk level and contributing factors communicated using appropriate language supported by adequate communication tools, can decide to participate to programs for personalized risk reduction if at higher risk, and benefit from cognitive enhancement interventions. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 43 trials of 327,264 participants with 42,016 major adverse cardiovascular events where included. 5 key findings →
Participants: 1,000 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cardiovascular disease risk factors begin in childhood and track into adulthood, increasing the possibility of impaired cardiometabolic health. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We will use results from this study to develop the first live video telehealth dyadic resiliency intervention focused on the prevention of chronic emotional distress in couples shortly after ADRD diagnoses. 2 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our study shows that ICERS of PFA combined with MI and MI alone amounted to €21,443 and €21,543 respectively per improved Z score point compared to the placebo and are below the WTP of €50,000 while the ICER of PFA alone amounted to €111,720 per improved Z score point. 3 key findings →
Participants: 1,525 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
9 of the 859 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →